Research Analysts’ Recent Ratings Updates for Harmony Biosciences (HRMY)

Harmony Biosciences (NASDAQ: HRMY) has recently received a number of price target changes and ratings updates:

• 2/28/2026 – Harmony Biosciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/25/2026 – Harmony Biosciences was downgraded by Zacks Research from “strong-buy” to “hold”.
• 2/25/2026 – Harmony Biosciences had its price target lowered by UBS Group AG from $46.00 to $36.00. They now have a “neutral” rating on the stock.
• 2/25/2026 – Harmony Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.
• 2/25/2026 – Harmony Biosciences had its price target lowered by Needham & Company LLC from $46.00 to $44.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Harmony Biosciences had its price target lowered by Bank of America Corporation from $32.00 to $28.00. They now have an “underperform” rating on the stock.
• 2/23/2026 – Harmony Biosciences was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”. They now have a $31.00 price target on the stock.
• 2/23/2026 – Harmony Biosciences was downgraded by Truist Financial Corporation from “buy” to “hold”.
• 2/19/2026 – Harmony Biosciences was given a new $50.00 price target by Mizuho.
• 2/11/2026 – Harmony Biosciences was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $46.00 price target on the stock, up from $43.00.
• 1/22/2026 – Harmony Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.

Insiders Place Their Bets

In related news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the sale, the chief financial officer owned 24,521 shares of the company’s stock, valued at approximately $910,955.15. The trade was a 13.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 50,640 shares of company stock valued at $1,932,256. 23.60% of the stock is currently owned by corporate insiders.

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.